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Abstract
Background: Alternative mRNA splicing of αi2, a heterotrimeric G protein α subunit, has been
shown to produce an additional protein, termed sαi2. In the sαi2 splice variant, 35 novel amino acids
replace the normal C-terminal 24 amino acids of αi2. Whereas αi2 is found predominantly at
cellular plasma membranes, sαi2 has been localized to intracellular Golgi membranes, and the
unique 35 amino acids of sαi2 have been suggested to constitute a specific targeting signal.
Results: This paper proposes and examines an alternative hypothesis: disruption of the normal C-
terminus of αi2 produces an unstable protein that fails to localize to plasma membranes. sαi2 is
poorly expressed upon transfection of cultured cells; however, radiolabeling indicated that αi2 and
sαi2 undergo myristoylation, a co-translational modification, equally well suggesting that protein
stability rather than translation is affected. Indeed, pulse-chase analysis indicates that sαi2 is more
rapidly degraded compared to αi2. Co-expression of βγ rescues PM localization and increases
expression of sαi2. In addition, αi2A327S, a mutant previously shown to be unstable and defective
in guanine-nucleotide binding, and αi2(1–331), in which the C-terminal 24 amino acids of αi2 are
deleted, show a similar pattern of subcellular localization as sαi2 (i.e., intracellular membranes
rather than plasma membranes). Finally, sαi2 displays a propensity to localize to potential
aggresome-like structures.
Conclusions: Thus, instead of the novel C-terminus of sαi2 functioning as a specific Golgi targeting
signal, the results presented here indicate that the disruption of the normal C-terminus of αi2
causes mislocalization and rapid degradation of sαi2.
Background
Heterotrimeric G proteins couple agonist-activated hepta-
helical receptors to a variety of effector responses. For the
most part, this signaling activity takes place at the plasma
membranes of cells. However, G proteins have been de-
tected at a variety of subcellular locations and have been
implicated in numerous membrane trafficking activities
[1,2]. This suggests that distinct, though not yet deter-
mined, mechanisms exist to target G protein subunits to
subcellular locations other than plasma membranes
(PM). Furthermore, post-transcriptional or post-transla-
tional modifications may play a role in directing a G pro-
tein subunit to a specific intracellular location.
Unique subcellular localization has been observed for a
novel alternative spliced form of the G protein α subunit
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(Gα), αi2[3]. This αi2 splice variant, termed sαi2, contains
a novel 35 amino acid sequence that replaces the C-termi-
nal 24 amino acids of αi2[3]. sαi2 has been observed to lo-
calize to Golgi membranes and other intracellular
membranes [3,4]; in contrast, wild type αi2 is typically
found at PM. Based on this unique localization of sαi2, a
prominent role in membrane trafficking has been pro-
posed for this subunit [3]. However, no report to date has
supported a functional role for sαi2 in vesicular transport,
although a variety of functional assays have implicated
other Gα, including αs and αi3, in vesicle trafficking path-
ways [1,2].
In spite of its unknown functional significance, sαi2 pro-
vides a potential model for studying mechanisms of sub-
cellular localization of Gα. Clearly, some aspect of the
novel splicing is responsible for the difference in subcellu-
lar targeting of sαi2 (i.e., Golgi and intracellular mem-
branes) compared to wild type αi2 (i.e., PM). To address
the mechanism of subcellular localization of sαi2, two hy-
potheses were tested herein. First, the possibility was test-
ed that the novel 35 amino acid sequence found at the C-
terminus of sαi2 functions as a specific Golgi or intracellu-
lar membrane targeting motif. A second possibility was
suggested by considering the location of the splice site.
Several studies have shown that deletions or amino acid
substitutions in the extreme C-terminal region of Gα cre-
ates a protein defective in guanine-nucleotide binding [5–
10]. Rapid release of guanine-nucleotides can result in an
unstable Gα [9,10]. This leads to the prediction that sαi2
is also unstable due to a disruption in the structure of its
C-terminus caused by the novel splice sequence. Thus, the
second possibility is that failure of sαi2 to localize at the
PM but instead localize at intracellular membranes is the
result of a general defect in protein stability. Results pre-
sented herein are consistent with this second hypothesis.
Results
αi2 and sαi2 differ only at their extreme C-termini. Alter-
native splicing results in a novel 35 amino acids in sαi2
that replace the C-terminal 24 amino acids of αi2 (Figure
1). In the studies presented here, both αi2 and sαi2 con-
tain an internal EE epitope, as used previously for
αi2[11,12]. The use of the EE epitope allows the direct
comparison of subcellular localization and expression of
αi2 and sαi2, and facilitates immunoprecipitation of the
two expressed proteins. This is essential since suitable an-
tibodies to detect and immuno-isolate sαi2 are not readily
available. Attempts to use a previously described polyclo-
nal antibody directed against the C-terminus of sαi2[3,4]
were unsatisfactory in our hands. In particular, attempts
to detect endogenous sαi2 by immunofluorescence failed
due to faint detection that showed drastically different
patterns of staining depending upon fixation technique.
The subcellular localization of expressed αi2 and sαi2 was
compared in COS and BHK cells (Figure 2). In both cell
types, αi2 was detected at cellular plasma membranes as
highlighted by bright staining at the cell periphery (Figure
2A and 2C). In contrast, sαi2 was not detected at plasma
membranes, but instead typically displayed an intracellu-
lar and perinuclear staining pattern (Figure 2B and 2D),
consistent with localization to intracellular membranes as
previously described [3,4]. The subcellular localization of
sαi2 showed overlap in immunofluorescent staining with
the Golgi protein, β-COP (Figure 3A and 3B) and the en-
doplasmic reticulum protein PDI (Figure 3C and 3D); lo-
calization of sαi2 exclusively to Golgi was not observed,
even at the lowest levels of detection. Subcellular fraction-
ation confirmed that sαi2 was localized, at least partly, to
membranes (Figure 2E). After lysis of cells in hypotonic
buffer followed by high-speed centrifugation, αi2 was
found predominantly in the particulate fraction from
COS (Figure 2E, lanes 3 and 4) or BHK cells (Figure 2E,
lanes 9 and 10). A majority of sαi2 was also detected in the
particulate fraction from both COS (Figure 2E, lanes 5 and
6) and BHK cells (Figure 2E, lanes 11 and 12), although
some was also found in the soluble fraction. As a compar-
ison, a non-palmitoylated mutant of αq, in which
cysteines 9 and 10 have been substituted with serines, is
found predominantly in the soluble fraction (Figure 2E,
lanes 7 and 8), as described previously [13]. Surprisingly,
in comparison to αi2, sαi2 was always detected in fewer
cells, by immunofluorescence analysis, and showed lower
levels of protein expression, by western blot analysis of
subcellular fractions (Figure 2E) or whole cell lysates (not
shown). These expression differences suggested that sαi2
was either less efficiently expressed or more rapidly de-
graded compared to αi2, as described below.
The C-terminal 35 amino acids of sαi2, which replace the
C-terminal 24 amino acids of αi2 (Figure 1), have been
proposed to function as a Golgi targeting signal [3,4]. To
test the potential importance of this C-terminal region in
localization of sαi2 to intracellular membranes and pre-
vention of sαi2 from localizing to PM, a deletion mutant
of αi2 was constructed consisting of amino acids 1–331.
In sαi2, the C-terminal splice occurs just after amino acid
331 (Figure 1), and thus the novel 35 amino acid splice se-
quence is removed in αi2(1–331). Immunofluorescence
microscopy indicates that αi2(1–331) (Figure 4B) displays
a subcellular localization pattern very similar to sαi2 (Fig-
ure 4A). This result is consistent with the alternative hy-
pothesis that a disruption of αi2 at the C-terminus creates
a protein unable to localize at the PM.
If the unique C-terminal 35 amino acid sequence of sαi2
functions as a Golgi targeting signal, it is important to test
whether it is sufficient to target a heterologous protein to
intracellular membranes. When the 35 amino acid se-
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quence was fused to the C-terminus of GFP (GFP-
sαi235aa), this unique sαi2 sequence failed to direct GFP
to intracellular membranes (Figure 5B); GFP-sαi235aa
was diffusely distributed throughout the cytoplasm and
nucleus, similar to what is observed for GFP alone (Figure
5A). On the other hand, when the first ten amino acids of
αi2 are fused to GFP to create αi2(1-10)-GFP, fluorescence
is detected strongly at the PM (Figure 5C), indicating the
N-terminus of αi2, which contains the sites for myristoyla-
tion and palmitoylation [14], can be sufficient for direct-
ing PM localization of a normally cytosolic protein. In
agreement with these results, the sαi2 C-terminal se-
quence failed to redirect the localization of a secreted or a
nuclear protein [4]. Thus, not only is the unique sαi2 se-
quence unable to override other localization signals, it is
unable to target a cytoplasmic protein to intracellular
membranes. These results are consistent with a lack of a
specific role for the sαi2 sequence in Golgi membrane tar-
geting.
The above experimental results failed to support the hy-
pothesis that the unique 35 amino acid sequence from
sαi2 serves as a specific Golgi or intracellular membrane
targeting motif. Thus, the following experiments concen-
trated on addressing the alternative hypothesis: sαi2 is un-
stable and rapidly degraded due to disruptions in the C-
terminus, and such instability results in a failure of sαi2 to
reach its proper place at the PM.
The ability of αi2 and sαi2 to undergo N-terminal lipid
modifications was compared. Myristoylation occurs co-
translationally at the extreme N-terminal glycine, while
palmitoylation occurs post-translationally at a cysteine
immediately after the myristoylated glycine [15]. The sub-
cellular site where palmitoylation occurs has not been
well defined, although in one model palmitoylation oc-
curs at the PM [16]. Cells expressing αi2 or sαi2 were met-
abolically labeled with 3H-palmitate or 3H-myristate. αi2
and sαi2 were immunoprecipitated from cell extracts, and
incorporation of radio-label was analyzed by SDS-PAGE
followed by fluorography (Figure 6A). No palmitoylation
of sαi2 was detected (Figure 6A, lane 3), although αi2 was
strongly palmitoylated (Figure 6A, lane 2). In contrast,
both αi2 and sαi2 incorporated similar levels or myristate
(Figure 6A, lanes 5 and 6). The similar level of myristoyla-
tion was particularly surprising since total sαi2 protein
was much lower than αi2 as determined by immunoblot-
ting of the immunoprecipitates (Figure 6B, compare lanes
5 and 6). Myristoylation is a co-translational modifica-
tion, and levels of radio-labeling should thus reflect syn-
thesis of new protein. Accordingly, the myristoylation
results (Figure 6A and 6B, lanes 5 and 6) strongly suggest-
ed that αi2 and sαi2 are translated equally well, as evi-
denced by similar levels of radiolabeled myristate
incorporation during the labeling period, but sαi2 is more
rapidly degraded, as seen by reduced steady-state levels of
immunoprecipitated protein. The lack of palmitoylation
of sαi2 is consistent with at least two, not necessarily mu-
tually exclusive, possibilities. sαi2 may fail to undergo
palmitoylation because it is not stable long enough for
post-translational palmitoylation to occur or because it
fails to reach a PM site of palmitoylation. Alternatively,
the novel C-terminal sequence of sαi2 may somehow pre-
vent direct recognition by a palmitoyl transferase.
Cells expressing high levels of sαi2, and to a much lesser
extent αi2, often displayed very bright intracellular accu-
mulations of sαi2 as visualized by immunofluorescence.
These large spots were reminiscent of recently described
aggresomes, accumulations of misfolded protein that are
being targeted for proteasome-dependent degradation
[17,18]. This observation suggested the possibility that in-
tracellular localization of sαi2 may reflect targeting to a
proteasome-dependent degradative pathway. To test this
idea further, cells expressing αi2 or sαi2 were treated with
the proteasome inhibitor acetyl-leucyl-leucyl-norleucinal
(ALLN) and changes in localization of the α subunit were
analyzed by immunofluorescence (Figure 7). After 1h
Figure 1
C-termini of G protein α subunits An alignment of C-terminal amino acids of selected Gα is shown. The arrow indicates
the site at which a novel 35 amino acids in sαi2 replaces the C-terminal 24 amino acids of αi2. Amino acid numbering is indi-
cated in parentheses. Secondary structure is indicated at the bottom [19].
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treatment with ALLN, αi2 localization is relatively unaf-
fected (Figure 7C), but sαi2 begins to show a slight in-
crease in distinct intracellular accumulations (Figure 7D).
At 4 h ALLN treatment, many cells expressing αi2 display
a decrease in PM localization and an increase in intracel-
lular staining (Figure 7E). αi2 is typically seen in large
bright spots and in a perinuclear/intracellular membrane
staining pattern after incubation of cells for 4 h with
ALLN. In fact, the localization pattern of αi2 after 4 h in-
cubation with ALLN (Figure 7E) is similar to the observed
localization of sαi2 in the absence or presence of ALLN
treatment (Figure 7B, 7D, and 7F). At 8 h treatment with
ALLN, both αi2 (Figure 7G) and sαi2 (Figure 7H) are de-
tected almost exclusively as a large bright spot in each ex-
pressing cell. Similar results were obtained using another
proteasome inhibitor, MG-132. Interestingly, ALLN treat-
ment was relatively ineffective at promoting accumula-
tion of overexpressed αs in aggresome-like structures (not
shown). Thus, the results of Figure 7 are consistent with
the proposal that the intracellular localization of sαi2 is
due to its targeting to a degradative pathway, a pathway
shared by αi2.
The subcellular localization of sαi2 was compared to
αi2A327S. This alanine to serine mutation in the C-termi-
nal region of αi1 (A326S) and αs (A366S) has been shown
to greatly accelerate GDP release, to accelerate irreversible
inactivation in vitro, and to cause rapid turnover of the α
Figure 2
Localization of αi2 and sαi2 Expression vectors encoding
αi2 (A and C) or sαi2 (B and D) were transiently transfected
into COS-7 (A and B) or BHK (C and D) cells. Subcellular
localization of the proteins was visualized by immunofluores-
cence microscopy using the EE monoclonal antibody fol-
lowed by a Texas Red conjugated anti-mouse antibody, as
described in "Materials and Methods". Bar, 10 µm. E,
pcDNA3 (lanes 1, 2), EE-αi2-pcDNA3 (lanes 3, 4, 9, 10), EE-
sαi2-pcDNA3 (lanes 5, 6, 11, 12) or EE-αqC9,10S-pcDNAI
were transiently transfected into COS-7 (lanes 1–8) or BHK
(lanes 9–12) cells. Cell lysates were separated into particu-
late (P) and soluble (S) fractions, as described in "Materials
and Methods". EE-tagged Gα subunits were detected at 41–
45 kDa (double asterisk) by immunoblotting with the EE
monoclonal antibody. A slightly smaller protein is consist-
ently detected (denoted by single asterisk) by the EE anti-
body, and this background band fractionates exclusively to
the soluble fraction.
Figure 3
Localization of sαi2 to Golgi and ER membranes sαi2
was expressed in COS-7 cells. 48 h after transfection, cells
on coverslips were fixed and processed for immunofluores-
cence. Co-localization of sαi2 (A) and the Golgi protein, β-
COP (B), was visualized after incubation of cells with the EE
antibody and a rabbit polyclonal anti-β-COP antibody fol-
lowed by Alexa 594 anti-mouse and Alexa 488 anti-rabbit
antibodies. Co-localization of sαi2 (C) and the endoplasmic
reticulum protein, protein disulfide isomerase (PDI) (D), was
visualized after incubation of cells with the EE antibody and a
rabbit polyclonal anti-PDI antibody followed by Alexa 594
anti-mouse and Alexa 488 anti-rabbit antibodies.
BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/12
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subunit in cultured cells [9,10]. Thus, if the observed in-
tracellular localization of sαi2 is caused by instability of
the protein due to disruptions at its C-terminus, then it
follows that αi2A327S should show a similar pattern of lo-
calization. Indeed, immunofluorescence microscopy re-
vealed a pronounced intracellular distribution for
αi2A327S (Figure 8E). In addition to intracellular mem-
brane localization similar to sαi2 (Figure 8C), αi2A327S
was detected weakly but consistently at the PM. It seems
likely that the C-terminal disruption of sαi2 (replacing the
24 C-terminal amino acids) is a more severe disruption
than the A327S substitution. Thus, the similarity in local-
ization of sαi2 and αi2A327S bolsters the idea that mislo-
calization of sαi2 is caused by its inherent instability.
G protein βγ subunits can stabilize wild type and alanine
to serine mutant α subunits in vitro[10]. Thus, the effect of
βγ co-expression on subcellular localization of αi2A327S
and sαi2 was tested. αi2 localizes to the PM efficiently
when expressed alone (Figure 8A) or when co-expressed
with βγ (Figure 8B). sαi2 shows a dramatic change in lo-
calization when co-expressed with βγ (Figure 8D), dis-
playing strong PM staining. Not only is sαi2 targeted
efficiently to the PM when co-expressed with βγ, but βγ co-
expression increases overall levels of transiently expressed
sαi2 and αi2, as determined by immunoblotting (Figure
8G), and increases the number of cells expressing sαi2, as
observed by immunofluorescence microscopy (not
shown). Similarly, co-expression of βγ efficiently pro-
motes PM localization of αi2A327S (Figure 8F).
The analysis of the effect of βγ was extended by examining
the localization of αi2 or sαi2 after co-transfection with βγ
and after treatment with ALLN. In contrast to Figure 7, a
marked difference was observed between αi2 and sαi2 af-
ter ALLN treatment. When βγ is co-expressed with αi2, PM
localization of αi2 is observed, as shown in Figure 8B, and
incubation with ALLN for 8 h shows little effect on PM lo-
calization of αi2 (Figure 9A). When βγ is co-expressed with
sαi2, PM localization of sαi2 is observed, as shown in Fig-
ure 8D, but incubation with ALLN for 8 h causes an in-
crease in bright intracellular accumulations of sαi2 (Figure
9B). Taken together, results with βγ co-expression are con-
sistent with the ability of βγ to promote PM targeting of
Gα, and further suggest that sαi2 is less effectively stabi-
lized than αi2 by βγ, as evidenced by ALLN-induced accu-
mulation in intracellular aggregates (Figure 9B).
Figure 4
Localization of sαi2 and αi2(1–331) Expression vectors
encoding sαi2 (A) or αi2(1–331) (B) were transiently trans-
fected into COS-7 cells. 48 h after transfection, subcellular
localization of the proteins was visualized by immunofluores-
cence microscopy using the EE monoclonal antibody fol-
lowed by Alexa 594 anti-mouse antibody, as described in
"Materials and Methods".
Figure 5
C-terminal 35 amino acids of sαi2 do not affect GFP
localization Expression vectors encoding GFP (A), GFP-
sαi235aa (B), or αi2(1-10)-GFP (C) were transfected into
HEK293 cells. 48 h after transfection, cells were fixed on
coverslips, and subcellular localization was determined by flu-
orescence microscopy visualization of GFP.
Figure 6
Myristoylation and palmitoylation of αi2 and sαi2
COS-7 cells were transfected with pcDNA3 (lanes 1 and 4),
or pcDNA3 containing αi2 (lanes 2 and 5) or sαi2 (lanes 3
and 6). 48 h after transfection, cells were incubated with 1.0
mCi/ml 3H-palmitate (lanes 1–3) or 0.5 mCi/ml 3H-myristate
(lanes 4–6) for 2 h. Following immunoprecitation with the EE
antibody, duplicate samples were resolved by SDS-PAGE.
Radiolabeled proteins were visualized by fluorography (panel
A), and immunoblotting with the EE antibody provides a
comparison of protein levels of αi2 and sαi2 (panel B).
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Figure 7
Effect of ALLN on αi2 and sαi2 localization αi2 (A, C, E,
and G) or sαi2 (B, D, F, and H) was expressed in BHK cells.
48 h after transfections cells were incubated in the absence
(A and B) or presence of 20 µg/ml ALLN for 1 h (C and D), 4
h (E and F), or 8 h (G and H). Cells were fixed and processed
for immunofluorescence using the EE antibody followed by
an Alexa 488 conjugate anti-mouse antibody. Bar, 10 µm.
Figure 8
Localization of αi2, sαi2, and αi2A327S and the effect
of βγ Expression vectors encoding αi2 (A and B), sαi2 (C and
D), or αi2A327 (E and F) were transfected alone (A, C, and
E) or together with expression vectors for β1 and γ2 (B, D,
and F) into BHK cells. Proteins were visualized by immun-
ofluorescence microscopy using the EE monoclonal antibody
followed by an Alexa 488 conjugate anti-mouse antibody.
Bar, 10 µm. G, EE-αi2-pcDNA3 (lanes 1 and 2) or EE-sαi2-
pcDNA3 (lanes 3 and 4) were transfected into COS-7 cells
alone (lanes 1 and 3) or with co-transfection of vectors
encoding β1 and γ2 (lanes 2 and 4). Immunoblotting with the
EE antibody detected αi2 or sαi2. Note that sαi2 expressed
alone (lane 3) is very weakly detected and barely visible in
this total cell lysate.
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Lastly, 35S-methionine pulse-chase labeling studies direct-
ly confirmed that sαi2 was more rapidly degraded than αi2
(Figure 10). After transient expression of the α subunits,
cellular proteins were radiolabeled with a brief pulse of
35S-methionine followed by a chase. Immunoprecipita-
tion of the α subunit after increasing times of chase, fol-
lowed by SDS-PAGE and fluorography revealed that
radiolabeled sαi2 was rapidly lost. αi2 consistently dis-
played a 3–4 fold longer half-life compared to sαi2, while
αi2A327S was intermediate. In the experiment presented
in Figure 10, the t1/2 was determined to be approximately
90, 180, and 360 min for sαi2, αi2A327S, and αi2, respec-
tively. Although this trend was consistent, the exact t1/2
showed some variability from experiment to experiment,
probably due to varying levels of transient overexpression.
It is likely that the difference in turnover of sαi2 and αi2 is
even more profound when the proteins are expressed at
lower levels. Consistent with this idea, sαi2 was refractory
to stable expression even though cells stably expressing
αi2 were easily selected (not shown). The inability to iso-
late cells stably expressing sαi2 can be attributed to its rap-
id degradation. Regardless, 35S-methionine pulse-chase
labeling studies (Figure 10) demonstrate that sαi2 is in-
deed more rapidly degraded than αi2.
Discussion
In addition to their well characterized role at the PM in
coupling activated GPCRs to effector proteins, heterot-
rimeric G proteins have been implicated in a variety of
other cellular functions, including membrane trafficking
pathways. A splice variant of αi2, termed sαi2, has been
proposed as a candidate to regulate vesicle transport due
to its localization at intracellular membranes. The studies
described in this report were undertaken to define mech-
anisms that underlie subcellular localization of sαi2. The
novel 35 amino acids found in sαi2 appear not to function
as a specific Golgi or endoplasmic reticulum targeting se-
quence. Instead, the results in this study support the pro-
posal that sαi2 fails to target to the PM because it is an
unstable protein. The following results support this hy-
pothesis: 1) sαi2 and αi2 are equally labeled by a pulse of
3H-myristate, although much less sαi2 protein is detected;
2) sαi2 displays a propensity to localize to potential aggre-
some-like structures, and this localization is greatly en-
hanced by proteasome inhibitor treatment; 3) the
αi2A327S mutant, previously shown to be unstable and
defective in guanine-nucleotide binding, shows a similar
pattern of subcellular localization (i.e., intracellular mem-
branes rather than PM); 4) βγ over-expression increases
Figure 9
Effect of ALLN on αi2 and sαi2 localization when co-
expressed with βγ Expression vectors encoding αi2 (A) or
sαi2 (B) were transfected together with expression vectors
for β1 and γ2 into BHK cells. 48 h after transfections cells
were incubated in the presence of 20 µg/ml ALLN for 8 h.
Cells were fixed and processed for immunofluorescence
using the EE antibody followed by an Alexa 594 conjugate
anti-mouse antibody. Bar, 10 µm.
Figure 10
Pulse-chase analysis of αi2, sαi2, and αi2A327S Expres-
sion vectors encoding αi2, sαi2, or αi2A327 were transfected
into COS-7 cells. 48 h after transfection, cells were incu-
bated for 10 min in media containing 0.1 mCi/ml 35S Express
protein labeling mix. Cells were washed, and incubated in
regular media for the indicated times (chase). Cells were har-
vested, lysates were prepared, and immunoprecipitations
were performed using the EE antibody. Samples were
resolved by SDS-PAGE, and radiolabeled proteins were visu-
alized by fluorography (upper panel). Note that two bands
are present in the sαi2 lanes; the upper band represents full-
length sαi2 and quantitation of this band was used to deter-
mine a half-life. The lower band likely represents a degrada-
tion product of sαi2 that is itself degraded even faster.
Quantitation of the bands from the fluorograph was per-
formed by densitometry and plotted as degradation curves
(lower panel) for αi2 ('), sαi2 (O), and αi2A327 (∇). These
experiments were repeated and the average ± S.E. half-life
was determined as 237 ± 110, 150 ± 42, and 67 ± 21 min for
αi2 (n = 3), αi2A327 (n = 2), and sαi2 (n = 3), respectively.
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expression of sαi2 and promotes PM localization of sαi2
and αi2A327S, but βγ co-expression does not prevent sαi2
localization to potential aggresome-like structures when
cells are treated with proteasome inhibitors; and 5) pulse-
chase analysis indicates that sαi2 is rapidly degraded.
A number of reports have demonstrated that disruptions
in the C-termini of Gα cause reduced affinity for guanine-
nucleotides and protein instability. The C-terminal 30
amino acids of Gα consist of the β6-α5 loop, followed by
the α5 helix and finally several amino acids of flexible
structure (Figure 1) [19–21]. The β6-α5 loop stabilizes the
guanine ring of bound GDP or GTP, and mutations in this
region affect guanine-nucleotide binding. The A326S mu-
tation of αi1 and A366S mutation of αs (cognate to the
αi2A327S used in this study) were shown to cause greatly
decreased affinity for GDP [9,10]. Defective binding of
GDP leads to more Gα in the empty state (no bound gua-
nine-nucleotide), and this form of Gα is rapidly dena-
tured in vitro, as shown for αsA366S and αi1A326S [9,10].
Moreover, αsA366S was demonstrated to undergo rapid
degradation (t1/2 < 1 h) in stably transfected cells [9]. The
same mutation in αt has also been shown to greatly de-
crease guanine-nucleotide binding [5,22]. Additional
amino acids in the critical β6-α5 loop are important for
maintaining Gα integrity [7].
Although the α5 helix (Figure 1) does not directly contact
the bound guanine-nucleotide [19–21], it is clearly im-
portant for Gα structure and to maintain the proper orien-
tation of the β6-α5 loop. A recent study identified a
number of α5 helix residues in αt that when changed to
alanines increased rates of guanine-nucleotide exchange
(i.e., decreased affinity for guanine-nucleotides) [5]. Indi-
vidual mutation of amino acids in αt, cognate to T330,
N332, V333, F337 in αi2 (Figure 1), increased nucleotide
exchange rates [5]. Two of these critical amino acids,
N332 and V333 in αi2, are in fact the first two amino acids
that are replaced by the novel splicing in sαi2 (Figure 1).
Thus, one might speculate that the novel 35 amino acid
sequence in sαi2 would impair guanine-nucleotide bind-
ing and result in a unstable protein. Unfortunately, initial
attempts to directly show a defect in guanine-nucleotide
binding by sαi2, using a GTPγ S-dependent trypsin protec-
tion assay [23], were unsuccessful due, at least in part, to
the inability to solubilize expressed sαi2 from membranes
using a mild detergent (e.g., lubrol/polyoxyethylene 10-
lauryl ether).
The data in this report are consistent with a scenario in
which intracellular Golgi/ER localization of sαi2 reflects
its rapid degradation rather than specific targeting to a
subcellular organelle. Particularly compelling is the simi-
larity in subcellular localization of αi2A327S and sαi2
(Figure 8). In addition, the use of proteasome inhibitors
(Figures 7 and 9) suggest that sαi2 is degraded by a protea-
some pathway. The observed intracellular membrane
(ER) localization and proteasome inhibitor-induced juxt-
anuclear aggregate accumulation (aggresome) is consist-
ent with that reported for other proteins being degraded
by such a pathway [18,24]. When treated with proteasome
inhibitors, overexpressed wild type αi2 also accumulates
in aggresome-like structures (Figure 7), suggesting that Gα
may normally be degraded by a proteasome-dependent
pathway. However, over-expression of βγ prevents ALLN-
induced juxtanuclear accumulations of αi2 but not sαi2
(Figure 9). Although little is known regarding degradative
pathways for G proteins, sαi2 and other mutants (e.g.,
αi2A327S) may be valuable tools for defining such path-
ways.
The data presented here argue against a sequence specific
Golgi membrane targeting function for the novel 35 ami-
no acid sequence found in sαi2. The novel sequence of
sαi2 is not sufficient to direct other proteins to Golgi/ER
membranes. These 35 amino acids did not change the cy-
toplasmic localization of GFP (Figure 5). Similarly, a re-
cent report showed that the sαi2 35 amino acids were
unable to retain a secreted protein in intracellular mem-
branes and did not affect localization of a nuclear protein
[4]. However, in addition to causing rapid degradation,
one cannot rule out that the 35 amino acid sequence of
sαi2 functions somehow as part of a Golgi targeting motif
in the context of other regions of αi2, as suggested [4].
Other researchers have described a specific Golgi mem-
brane localization of sαi2[4]; in contrast, the results pre-
sented in this report always show a much more disperse
subcellular localization of sαi2 to intracellular mem-
branes consistent with staining of both Golgi and ER. The
reason for this difference in localization is unclear. Inter-
estingly, in the other study, the authors found that dele-
tion of a proline-rich sequence corresponding to sαi2
amino acids 348–359 (Figure 1) changed localization of
sαi2 from Golgi membranes to a more diffuse localization
throughout intracellular membranes [4]. However, muta-
tion of proline residues to alanines failed to affect sαi2 lo-
calization [4]. Thus, little evidence exists to support a
specific membrane targeting role for the novel sαi2 se-
quence.
βγ was able to promote plasma membrane localization of
sαi2 (Figure 8). βγ prevents irreversible inactivation of αi1,
when measured in vitro at 37°C, and slows the inactiva-
tion of αi1A326S [10]. Thus, βγ may stabilize sαi2 and
αi2A327S allowing βγ-dependent [25–29] PM localiza-
tion. These results are also consistent with the possibility
that the primary defect in sαi2 is a reduced ability to inter-
act with βγ; Gα containing mutations in known sites of
contact with βγ fail to localize to PM, but over-expression
of βγ can rescue their PM localization [28,29]. However,
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the crystal structures [30,31] show that the C-terminal β6-
α5 loop/α5 helix region does not directly contact βγ.
Thus, it is more likely that indeed sαi2 is deficient in bind-
ing to βγ, but this effect is a consequence of its instability.
sαi2 may exist in a state that does not interact well with βγ
simply because it is in the process of being irreversibly in-
activated [9,10]. Similarly, αi2A327S appears not to be de-
fective in its intrinsic ability to interact βγ [10], and co-
expression of βγ shifts αi2A327S, like sαi2, from intracel-
lular to plasma membranes (Figure 8).
What is the cellular function of sαi2? The ability of βγ to
promote PM localization of sαi2 raises the possibility that
endogenous sαi2 is in fact localized to PM where it can in-
teract with GPCRs and effectors. Future studies will test
the potential of sαi2, when co-expressed with βγ, to pro-
ductively interact with receptors and effectors. However,
this possibility is viewed as unlikely for several reasons.
First, others have shown that in COS-7 cells endogenous
sαi2 is not detected at PM but only found intracellularly
[3,4], although one cannot rule out that a small but func-
tionally significant fraction of sαi2 reaches the PM. Sec-
ond, the extreme C-termini of Gα are critical sites for
interaction with GPCRs [32], and the novel C-terminal se-
quence found in sαi2 would be predicted to disrupt pro-
ductive interactions with GPCRs. Third, even though βγ
can promote PM localization of sαi2 in the overexpression
system described here, sαi2 remains less stable than αi2
(Figure 9), suggesting that such instability may also im-
pair productive interactions with GPCRs.
On the other hand, unknown protein(s) may function to
stabilize sαi2 and help direct it to Golgi membranes. A
specific combination of β and γ subtypes may play such a
role; however, one thorough study showed a lack of βγ on
Golgi membranes of exocrine pancreatic cells even
though a variety of Gα were readily detected in the Golgi
[33]. Other proteins that may specifically promote the in-
tracellular targeting of Gα have not been identified.
It is possible that sαi2 functions as a short-lived protein
regulating some aspect of membrane transport pathways;
however, no experiments to directly support or refute this
hypothesis have been reported. Instead, it is tempting to
speculate that alternative splicing may be a mechanism to
regulate cellular levels of αi2. In this model, certain condi-
tions may favor the formation of sαi2 compared to αi2,
and the resulting rapid degradation of sαi2 would de-
crease the cellular content of αi2. A precedent for such al-
ternative splicing-dependent regulation of expression has
been described for H-ras [34]. Alternative splicing occurs
in H-ras, and the alternative spliced form is predicted to
encode an unstable transcript and a protein product that
lacks the ability to oncogenically transform cells. A muta-
tion was identified that abolishes the alternatively spliced
form, and this mutation leads to an increase in H-ras ex-
pression and transforming ability. Thus, it was demon-
strated that alternative splicing is a mechanism that cells
use to control expression of H-ras [34]. Alternative splic-
ing may similarly play an important role in regulating ex-
pression of αi2. Testing of this idea will require a
comparison of sαi2 and αi2 transcript levels, and an anal-
ysis of whether relative expression is affected in response
to physiological changes, such as extracellular stimuli or
cell differentiation.
Conclusions
In summary, the results presented here demonstrate that
sαi2, a novel splice variant of αi2, is rapidly degraded
when expressed in cells. Such instability is consistent with
known structure-function data regarding the importance
of the C-terminus of Gα subunits. The observed intracel-
lular localization of sαi2 is due, at least in part, to its insta-
bility. Moreover, the data presented in this study argue
against the novel C-terminus of sαi2 functioning as a spe-
cific Golgi targeting motif.
In addition, similarly to sαi2, an αi2 mutant, αi2A327S,
previously demonstrated to be unstable in vitro, displays a
defect in plasma membrane localization when expressed
in cells. These results suggest that both sαi2 and αi2A327S




Cell culture reagents were obtained from Mediatech.
[9,10-3H]palmitic acid, [9,10-3H]myristic acid, and 35S
Express labeling mix were from NEN. Acetyl-leucyl-leucyl-
norleucinal (ALLN) and MG-132 were from Calbiochem.
The EE monoclonal antibody was a gift from H. Bourne.
Other reagents were obtained from Fisher and Sigma.
Expression plasmids
EE-αi2-pcDNAI was obtained from H. Bourne (UCSF). In
this plasmid, mouse αi2 cDNA contains the EE epitope se-
quence EEYMPTE at codons 166 to 172 [11]. Mouse sαi2
cDNA was provided by E. Borrelli (Strasbourg) in the plas-
mid pSVsGi2. sαi2 was excised from pSVsGi2 using EcoRI
and SmaI and subcloned into the EcoRI and EcoRV sites
of pcDNAI to produce sαi2-pcDNAI. EE-tagged sαi2 was
constructed by subcloning a EcoRI-BglII fragment from
EE-αi2-pcDNAI into sαi2-pcDNAI. EE-tagged αi2A327S-
pcDNAI was obtained from J. Morales (UCSF). EE-tagged
αi2(1–331)-pcDNA3 was constructed by by PCR amplifi-
cation of the coding region for the amino acids 1 to 331
of αi2 using the T7 primer as the 5' primer and 5'-ccggctc-
gagtcacttggtgtcggtggcgcatg-3' as the 3' primer and using
EE-αi2-pcDNA3 as the template. The PCR amplified prod-
uct was digested with HindIII and XhoI and subcloned
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into the correspondingly digested EE-αi2-pcDNA3. GFP-
sαi235aa was constructed by PCR amplification of the
coding region for the C-terminal 35 amino acids of sαi2
using the 5' primer 5'-cgcagatctagaaaactttttaga-3' and the
3' primer 5'-cgcaagcttactcaaggcacggaatc-3'. The PCR frag-
ment was digested with BglII and HindIII and subcloned
into the correspondingly digested pEGFP-C1 (Clontech).




amino acids 1–10 of αi2) and ligating into AgeI-NheI di-
gested pEGFP-N1. Human β1-pCMV5 and bovine γ2-pcD-
NAI have been described [35].
Cell culture and transfection
BHK, HEK293, and COS-7 cells were cultured in DMEM
containing 10% fetal bovine serum. Transfections were
performed in 6-well plates or 6 cm culture dishes using
Lipofectamine (GibcoBRL) or FuGene6 (Roche) accord-
ing to the manufacturer's protocol.
Immunofluorescence localization
Cells were transfected in 6-well plates with 1 µg of the in-
dicated expression plasmid. In experiments where β1 and
γ2 expression plasmids were co-transfected with αi2 or
sαi2, the amounts of α, β, and γ plasmids used were 0.7,
0.2, and 0.1 µg, respectively. 24 h after transfection, cells
were replated onto glass coverslips and grown for an addi-
tional 24 h before fixing in methanol at -20°C for 20 min.
Cells were washed with PBS and then incubated in block-
ing buffer consisting of TBS (50 mM Tris, pH 7.5, 150 mM
NaCl) with 1% Triton X-100 and 2.5% nonfat milk. Cov-
erslips were then incubated in blocking buffer containing
20 µg/ml EE monoclonal antibody for 1 h. For dual local-
ization experiments, a 1:1000 dilution of a rabbit polyclo-
nal anti-β-coatomer protein (β-COP) antibody (Affinity
BioReagents) or a 1:200 dilution of a rabbit polyclonal
anti-protein disulfide isomerase (PDI) antibody (Stress-
Gen Biotechnologies) was included with the EE mouse
monoclonal. Following washes with blocking buffer, cells
were incubated in a 1:100 dilution of the indicated sec-
ondary antibody, either Alexa Fluor 488 or 594 goat anti-
mouse (Molecular Probes) or Texas Red donkey anti-
mouse (Jackson Immunoresearch) or Alexa Fluor 488
goat anti-rabbit (Molecular Probes), for 30 min. The cov-
erslips were washed and mounted on glass slides with
Prolong Antifade reagent (Molecular Probes, Eugene,
OR), and microscopy was performed with an Olympus
BX60 microscope equipped with a Sony DKC-5000 digital
camera. A minimum of 50 cells were examined for each
transfection. Transfections were repeated and representa-
tive pictures were taken of cells displaying a typical expres-
sion pattern for each transfection. Only cells displaying
low to intermediate levels of expression were utilized. Im-
ages were processed with Adobe Photoshop.
Subcellular Fractionation
Soluble and particulate fractions were isolated as previ-
ously described [29]. BHK or COS-7 cells were transfected
in 6 cm plates with 3 µg of the indicated expression plas-
mid. 24 h after transfection, the cells were transferred to
10-cm plates and grown for another 24 h. Cells were
washed with phosphate-buffered saline and then lysed in
0.5 ml hypotonic lysis buffer by 10 passages through a 27-
gauge needle. Cells were centrifuged at 200 × g for 5 min
to pellet nuclei and intact cells, and the supernatant was
then centrifuged at 150,000 × g for 20 min to obtain sol-
uble and particulate fractions. Fractions were resolved by
12% SDS-PAGE, transferred onto PVDF-Plus (Micron Sep-
arations, Inc) and probed with EE monoclonal antibody.
Bands were visualized by chemiluminescence.
Metabolic labeling and immunoprecipitation
COS-7 cells were transfected in 6 cm plates with 3 µg of
the indicated expression plasmid. 24 h after transfection,
cells were replated into 6 cm plates. For fatty acid labeling
experiments [36], one transfection was replated into two
6 cm plates. For 35S labeling experiments, cells from two
or three identical transfections were combined before re-
plating in multiple 6 cm plates. Incubation with radioiso-
tope was then performed 48 h after transfection.
For fatty acid labeling, cells in a 6 cm dish were incubated
with 1 ml of DMEM containing 10% dialyzed fetal bovine
serum, 5 mM sodium pyruvate, and [9,10-3H]palmitic
acid (1 mCi/ml) or [9,10-3H]myristate (0.5 mCi/ml) for 2
h. For 35S pulse-chase labeling, cells in a 6 cm dish were
washed with DMEM (without methionine), and then in-
cubated in DMEM (without methionine) containing 10%
dialyzed fetal bovine serum at 37°C for 1 h. Next, cells
were incubated in DMEM (without methionine) contain-
ing 10% dialyzed fetal bovine serum and 0.1 mCi/ml 35S
Express mix for 10 min. After the 10 min pulse labeling,
cells were either immediately lysed (see below) or washed
with normal growth media and then "chased" by incuba-
tion in normal growth media for the indicated times.
Fatty acid labeled and 35S methionine/cysteine labeled
samples were then identically processed by immunopre-
cipitation. Cells were washed once with ice-cold PBS and
lysed in 1 ml of Extraction buffer (50 mM HEPES, pH 8,
50 mM NaCl, 10 µM β-mercaptoethanol, 1% Triton X-
100, 1% sodium cholate, 1 mM PMSF, 2 µg/ml leupeptin,
and 2 µg/ml aprotinin). Cell extracts were tumbled for 1
h at 4°C, and nuclei and insoluble material were removed
by microcentrifugation at 16,000 × g for 3 min. Samples
were adjusted to 0.5% SDS. 10 µg of EE antibody was add-
ed, and the samples were tumbled for 2 h at 4°C. Next, 20
BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/12
Page 11 of 11
(page number not for citation purposes)
µl of Protein A/G PLUS agarose (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA) was added, and the sample was tum-
bled overnight at 4°C. The sample was centrifuged for 30
s at 200 × g to pellet the beads. The supernatant was dis-
carded, and the beads were washed 3 times with 1 ml Ex-
traction buffer. SDS-PAGE sample buffer containing 10
mM DTT was added to the washed beads, and the samples
were heated at 65°C for 1 min (3H fatty acid labeled sam-
ples) or boiled for 5 min (35S methionine/cysteine la-
beled samples). An aliquot was analyzed by 10% SDS-
PAGE. Gels were incubated for 20 min in an aqueous so-
lution of 50% methanol/10% acetic acid, followed by
10% ethanol/10% acetic acid for 20 min, and, finally,
Amplify (Amersham) for 20 min. Gels were dried and
subjected to fluorography at -80°C using Hyperfilm MP
(Amersham). For 35S pulse-chase experiments, intensity
of each labeled band was quantitated by densitometry.
Results were analyzed with GraphPad Prizm software to
determine a half-life.
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